TMDX Relative Valuation
TMDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TMDX is overvalued; if below, it's undervalued.
Historical Valuation
Transmedics Group Inc (TMDX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.12. The fair price of Transmedics Group Inc (TMDX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：139.07
Fair
53.92
PE
1Y
3Y
5Y
Trailing
Forward
31.12
EV/EBITDA
Transmedics Group Inc. (TMDX) has a current EV/EBITDA of 31.12. The 5-year average EV/EBITDA is -4.99. The thresholds are as follows: Strongly Undervalued below -195.69, Undervalued between -195.69 and -100.34, Fairly Valued between 90.36 and -100.34, Overvalued between 90.36 and 185.72, and Strongly Overvalued above 185.72. The current Forward EV/EBITDA of 31.12 falls within the Historic Trend Line -Fairly Valued range.
48.45
EV/EBIT
Transmedics Group Inc. (TMDX) has a current EV/EBIT of 48.45. The 5-year average EV/EBIT is -32.71. The thresholds are as follows: Strongly Undervalued below -298.89, Undervalued between -298.89 and -165.80, Fairly Valued between 100.38 and -165.80, Overvalued between 100.38 and 233.47, and Strongly Overvalued above 233.47. The current Forward EV/EBIT of 48.45 falls within the Historic Trend Line -Fairly Valued range.
6.98
PS
Transmedics Group Inc. (TMDX) has a current PS of 6.98. The 5-year average PS is 10.71. The thresholds are as follows: Strongly Undervalued below -1.50, Undervalued between -1.50 and 4.60, Fairly Valued between 16.81 and 4.60, Overvalued between 16.81 and 22.91, and Strongly Overvalued above 22.91. The current Forward PS of 6.98 falls within the Historic Trend Line -Fairly Valued range.
28.98
P/OCF
Transmedics Group Inc. (TMDX) has a current P/OCF of 28.98. The 5-year average P/OCF is 50.32. The thresholds are as follows: Strongly Undervalued below -353.94, Undervalued between -353.94 and -151.81, Fairly Valued between 252.45 and -151.81, Overvalued between 252.45 and 454.58, and Strongly Overvalued above 454.58. The current Forward P/OCF of 28.98 falls within the Historic Trend Line -Fairly Valued range.
51.66
P/FCF
Transmedics Group Inc. (TMDX) has a current P/FCF of 51.66. The 5-year average P/FCF is -6386.32. The thresholds are as follows: Strongly Undervalued below -55110.04, Undervalued between -55110.04 and -30748.18, Fairly Valued between 17975.54 and -30748.18, Overvalued between 17975.54 and 42337.40, and Strongly Overvalued above 42337.40. The current Forward P/FCF of 51.66 falls within the Historic Trend Line -Fairly Valued range.
Transmedics Group Inc (TMDX) has a current Price-to-Book (P/B) ratio of 13.47. Compared to its 3-year average P/B ratio of 16.06 , the current P/B ratio is approximately -16.15% higher. Relative to its 5-year average P/B ratio of 13.90, the current P/B ratio is about -3.13% higher. Transmedics Group Inc (TMDX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -3.23%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -3.80% , the current FCF yield is about -100.00% lower.
13.33
P/B
Median3y
16.06
Median5y
13.90
2.52
FCF Yield
Median3y
-3.23
Median5y
-3.80
Competitors Valuation Multiple
The average P/S ratio for TMDX's competitors is , providing a benchmark for relative valuation. Transmedics Group Inc Corp (TMDX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 32.24%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TMDX increased by 122.34% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 3.88 to 16.91.
The secondary factor is the Revenue Growth, contributed 32.24%to the performance.
Overall, the performance of TMDX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Transmedics Group Inc (TMDX) currently overvalued or undervalued?
What is Transmedics Group Inc (TMDX) fair value?
How does TMDX's valuation metrics compare to the industry average?
What is the current P/B ratio for Transmedics Group Inc (TMDX) as of Dec 05 2025?
What is the current FCF Yield for Transmedics Group Inc (TMDX) as of Dec 05 2025?
What is the current Forward P/E ratio for Transmedics Group Inc (TMDX) as of Dec 05 2025?